Intra-Cellular Therapies (ITCI) Sinks 69% as Trading Resumes

September 28, 2016 4:33 PM EDT

Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.

Intra-Cellular Therapies (NASDAQ: ITCI) sinks 68.7% as trading resumes following trial failure.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

FDA, Hot FDA News, Trader Talk, Trading Halts

Related Entities

The Children's Investment Fund (TCI)

Add Your Comment